Introduction
============

Threatened premature labor (TPTL) is a sign of giving birth in the middle and late stages of pregnancy before normal delivery (\<37 weeks). It is reported that 65% of pregnant women with TPTL will give birth prematurely (before 37 weeks) ([@b1-etm-0-0-8273]), while \~30% of hospitalized patients related to pregnancy are due to TPTL ([@b2-etm-0-0-8273]), and premature labor is still the leading cause of neonatal death and attack ([@b3-etm-0-0-8273],[@b4-etm-0-0-8273]). Some studies have shown that \~30% of premature labor is the result of spontaneous premature labor, and only \~10--15% of women with symptoms of premature labor will give birth within the next 2--7 days ([@b5-etm-0-0-8273]). Finding more effective treatment methods for premature labor is a serious problem that needs to be faced clinically.

Allylestrenol (AT) is an artificially synthesized progesterone, which can effectively treat abortion, TPTL, intrauterine growth restriction ([@b6-etm-0-0-8273]). Some studies have pointed out that AT has selective β-adrenergic effect mediated by nerves on myometrium β2 receptor, reducing myometrium activity, thus rapidly and effectively relaxing hypertonic myometrium within 24 h, and avoiding life-threatening emergencies of mothers, such as pulmonary edema and myocardial ischemia. Therefore, AT is a drug with minimal side effects and good patient compliance in progesterone use ([@b7-etm-0-0-8273],[@b8-etm-0-0-8273]). Ritodrine (RD) can effectively inhibit the contraction of uterine smooth muscle, reduce uterine activity and prolong pregnancy, and is a commonly used anti-uterine contraction drug for TPTL treatment ([@b9-etm-0-0-8273]). Some studies have comfirmed that AT combined with RD in the treatment of habitual abortion has achieved better efficacy than that of AT alone ([@b10-etm-0-0-8273]). In addition, studies have also verified that the initiation of labor is closely related to the regulation of inflammatory factors. Progesterone can maintain pregnancy by mediating the expression of relevant inflammatory factors, which can not only control the symptoms of premature labor, but also eliminate the real causes of labor ([@b11-etm-0-0-8273]).

Therefore, through prospective analysis, this study explores the efficacy of AT combined with RD on TPTL and its influence on inflammatory factors in peripheral blood, so as to provide reference for clinical treatment of TPTL.

Patients and methods
====================

### Patient data

Data of 206 patients with TPTL admitted to Zhongshan Hospital Affiliated to Fudan University from January 2017 to July 2018 were prospectively analyzed. They were aged 20--40 years, and were divided into two groups according to different drug application methods. Among them, 106 patients received AT combined with RD (research group) and 100 patients received AT combined with magnesium sulfate (MgSO~4~) (control group). Inclusion criteria were as follows: cases conformed to TPTL diagnostic criteria, patients with complete clinical data, those who did not use other combined drugs, those with no contraindication for continuing pregnancy or using fetal protection drugs. Exclusion criteria were as follows: patients with abnormal heart, liver, lung and kidney functions, patients with hypertension, diabetes, hyperthyroidism and other diseases, multiple births, polyhydramnios, congenital malformation of children, and patients with mental diseases or abnormal brain judgment. This study informed all patients and their families by letter or telephone and they signed an informed consent. The study was approved by the Ethics Committee of Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University (Shanghai, China).

### Intervention methods

Pregnant women were injected dexamethasone 6 mg intramuscularly after admission, 12 h each time, 4 times. The control group was injected with AT+MgSO~4~. Treatment: MgSO~4~ injection (Yangzhou Zhongbao Pharmaceutical Co., Ltd., SFDA approval no. H32024805) was used for treatment. The first loading dose was 8 g/h intravenous drip, followed by 1--2 g/h maintenance treatment until 12--24 h after uterine contraction inhibition, and the blood magnesium concentration was maintained at 2--3.5 mmol/l; at the same time, they were given AT tablets orally (Changzhou Siyao Pharmaceutical Co., Ltd., SFDA approval no. H20113293), one tablet (5 mg) each time, three times a day, until 37 weeks of pregnancy or childbirth. The research group was treated with AT+RD: 100 mg of RD injection (Guangdong Xianqiang Pharmaceutical Co., Ltd., SFDA approval no. H20090302) mixed with 500 ml of 5% glucose injection intravenously with an initial dose of 0.05 mg/min and an addition of 0.05--0.35 mg/min per minute until 0.10--0.40 mg/min. The treatment was maintained until 12--24 h after uterine contraction was inhibited. At the same time, oral administration of AT tablets was the same as that of the control group for the same number of times and dose until 37 weeks of pregnancy or childbirth.

### Observation indicators

General information of patients were collected, including age, height, weight, and gestational weeks. Enzyme-linked immunosorbent assay (Shanghai Xinfan Biotechnology Co., Ltd., XF130618) was used to detect the changes in the expression levels of IL-17, IL-10 and IL-6 in peripheral blood of patients before and after treatment. Prolonged pregnancy time, success rate of fetal protection and average delivery time of patients were recorded. The adverse pregnancy conditions of patients in the two groups were compared, including the Apgar score ([@b12-etm-0-0-8273]), birth weight and adverse conditions of the newborns, and postpartum hemorrhage and postpartum hospital stays of the research group were recorded.

### Statistical methods

SPSS 19.0 (Asia Analytics Formerly SPSS China) was used for analysis. Measurement data were expressed as \[n (%)\], and comparison of the rates between the two groups adopted χ^2^ test. Enumeration data were expressed as mean ± SD. Comparison between the two groups was conducted by independent-samples t-test, comparison at different time points in the group was conducted by repeated measures analysis of variance, and back testing was conducted by LSD test. A P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### General information

The gestational weeks of patients in the two groups were between 27 and 33 weeks, and there was no significant difference in age, height, weight, gestational weeks and mean arterial pressure between them (P\>0.05) ([Table I](#tI-etm-0-0-8273){ref-type="table"}).

### Analysis of pregnancy

The fetus protection rate in the research group was significantly higher than that in the control group, and the difference was statistically significant (P\<0.05). The prolonged pregnancy time in the research group was significantly better than that in the control group (P\<0.05). The average delivery time in the research group was also higher than that in the control group (P\<0.05) ([Table II](#tII-etm-0-0-8273){ref-type="table"}).

### Analysis of inflammatory factors in peripheral blood

After treatment, the levels of IL-17, IL-10 and IL-6 in serum of the two groups were significantly lower than those before treatment (P\<0.05). The expression levels of IL-17, IL-10 and IL-6 in serum of the research group were significantly lower than those of the control group (P\<0.05) ([Table III](#tIII-etm-0-0-8273){ref-type="table"}).

### Analysis of Apgar score and birth weight of newborns

Apgar scores of newborns in research group and control group were 9.48±0.26 and 8.97±0.18, respectively, and birth weight was 3054.51±641.98 g and 2423.26±756.10 g, respectively. Apgar scores and neonatal weight of patients in the research group were significantly higher than those in the control group, and the difference was statistically significant (P\<0.05) ([Fig. 1](#f1-etm-0-0-8273){ref-type="fig"}).

### Analysis of adverse reactions of patients during treatment

During treatment, the number of patients with adverse reactions such as headache, chest discomfort, myasthenia and respiratory depression in the research group were 6 (5.66%), 6 (5.66%), 4 (3.77%) and 5 (4.72%), while the number of patients with adverse reactions in the control group were 16 (16%), 14 (14%), 14 (14%) and 15 (15%), respectively. The proportion of patients in the research group with adverse reactions was significantly lower than that in the control group, and the difference was statistically significant (P\<0.05) ([Fig. 2](#f2-etm-0-0-8273){ref-type="fig"}).

### Analysis of adverse factors

There were 2 cases of neonatal death in the control group, but none in the research group, and no significant difference. However, the newborns in the research group with malformation and asphyxia were significantly fewer than those in the control group, and the difference was statistically significant (P\<0.05) ([Table IV](#tIV-etm-0-0-8273){ref-type="table"}).

### Comparison of postpartum hemorrhage and postpartum hospital stays

Postpartum hemorrhage and postpartum hospital stays in the research group were significantly fewer than those in the control group, and the difference was statistically significant (P\<0.05) ([Table V](#tV-etm-0-0-8273){ref-type="table"}).

Discussion
==========

TPTL is the main cause of perinatal morbidity and mortality in many countries, including the USA. Neonatal mortality, respiratory distress syndrome, intraventricular hemorrhage and other diseases are negatively correlated with gestational age at birth ([@b13-etm-0-0-8273]), and a study indicates that TPTL is a risk factor for impaired cognitive development at the age of 2 years. Cognitive ability of premature children is significantly lower than that of full-term children ([@b14-etm-0-0-8273]). TPTL seriously threatens the life and health of newborns and affects cognitive growth. Therefore, clinical treatment for TPTL requires better efficacy. Some studies have pointed out that AT can effectively prolong the pregnancy time of TPTL patients and can effectively reduce the messenger nucleotide level of oxytocin receptor ([@b15-etm-0-0-8273]). In addition, progesterone has a limited effect on acute uterine contraction, but it may play a role in preventing premature delivery or be regarded as a sensitizer of other uterine contraction agents ([@b16-etm-0-0-8273]). RD, as the only drug approved by the US Food and Drug Administration for anti-uterine contraction, has significant anti-uterine contraction efficacy on TPTL ([@b17-etm-0-0-8273]). There are many clinical reports on the treatment of TPTL with combination drugs. For example, RD combined with nifedipine can prolong pregnancy \>7 days more effectively than RD alone ([@b18-etm-0-0-8273]), and there is no obvious difference in the efficacy and adverse reactions between RD and MgSO~4~ ([@b19-etm-0-0-8273]). However, there are few reports on AT combined with RD in the treatment of TPTL. Therefore, through prospective analysis, this study explored the efficacy of AT combined with RD in the treatment of TPTL and its influence on inflammatory factors in peripheral blood, so as to provide reference for clinical treatment of TPTL.

This study showed that after treatment, the pregnancy rate, prolonged pregnancy time and average delivery time in the research group were significantly higher than those in the control group. The Apgar score and neonatal weight of patients in the research group were significantly better than those in the control group. During treatment, the adverse reactions of patients in the research group and overall adverse conditions of newborns were significantly better than those in the control group.

Under normal circumstances, embryos are not rejected by mothers, which depends on the immune tolerance of mother-fetus interface and the balance between cytokines. Once this immune tolerance pattern is destroyed, habitual abortion will occur ([@b20-etm-0-0-8273]). The cervical vagina or intrauterine infection process during pregnancy is an extremely fragile state for the mothers and fetuses. The immune defense process induces the pro-inflammatory environment and damages the immune privilege in the uterine cavity. Nearly 30% of premature women have microbial invasion or inflammation in the amniotic cavity, which results in increase of interleukin and tumor necrosis factor, leading to disruption of fetal tolerance ([@b21-etm-0-0-8273]). Progesterone has a strong immunoregulation effect and is of great significance to physiological immune tolerance when lying in bed ([@b22-etm-0-0-8273]). Progesterone has an effect on interleukin production in vaginal and cervical epithelial cells, inhibits vaginal epithelial cell base and bacterial stimulation of interleukin production, and induces changes in the concentration of inflammatory factors in cervical secretions ([@b23-etm-0-0-8273],[@b24-etm-0-0-8273]). We studied and measured the changes of IL-17, IL-10 and IL-6 levels in serum of the two groups. Our study indicated that the levels of IL-17, IL-10 and IL-6 in serum of the two groups after treatment were significantly lower than those before treatment. The expression levels of IL-17, IL-10 and IL-6 in serum of the research group after treatment were significantly lower than those in the control group. AT combined with RD can effectively reduce the level of inflammatory factors, prevent the immune destruction of the body and effectively maintain the body balance. This is one of the reasons why the efficacy of patients in the research group is obviously better than that of the control group. In addition, this study indicated that IL-6, IL-8 and IL-10 might be developed as factors for predicting TPTL in the future, which also verified the role of inflammatory factors in TPTL ([@b25-etm-0-0-8273]).

In the present study, we obtained results showing that the effects of AT combined with RD on TPTL were better than that of AT combined with MgSO~4~. However, further studies are necessary with larger sample size for confirmation.

In conclusion, AT combined with RD in the treatment of TPTL can significantly reduce the expression levels of IL-17, IL-10 and IL-6, reduce adverse pregnancy conditions, prolong gestational weeks, and has higher safety and better application value.
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###### 

General information.

                                         Control group (n=100)   Research group (n=106)   χ^2^/t   P-value
  -------------------------------------- ----------------------- ------------------------ -------- ---------
  Age                                    27.42±5.65              27.68±5.49               0.335    0.738
  Height (cm)                            158.57±5.65             159.14±5.84              0.735    0.463
  Weight (kg)                            55.36±5.48              54.69±5.98               0.837    0.404
  Gestational weeks (week)               29.68±2.89              29.44±3.10               0.574    0.567
  Mean arterial pressure (mmHg)          80.56±15.44             82.67±14.96              0.996    0.320
  Cervical length (mm)                   13.42±4.26              13.56±4.01               0.243    0.808
  Abdominal circumference (cm)           24.84±2.26              24.66±2.37               0.557    0.578
  Fetal heart rate (times/min)           120.65±21.77            123.85±20.64             1.803    0.280
  History of premature labor \[n (%)\]                                                    0.011    0.918
    Yes                                  54 (54)                 58 (54.72)                        
    No                                   46 (46)                 48 (45.28)                        

###### 

Analysis of pregnancy.

                                    Control group (n=100)   Research group (n=106)   χ^2^/t   P-value
  --------------------------------- ----------------------- ------------------------ -------- ---------
  Fetal protection \[n (%)\]                                                         4.903      0.027
    Success                         85 (85)                 98 (92.45)                        
    Failure                         15 (15)                 8 (7.55)                          
  Prolonged pregnancy time (days)   21.54±18.68             34.68±23.58              4.416    \<0.001
  Average delivery time (weeks)     35.21±3.68              37.54±3.86               4.429    \<0.001

###### 

Analysis of inflammatory factors in peripheral blood (pg/ml).

                       Control group (n=100)                                       Research group (n=106)                                      t       P-value
  -------------------- ----------------------------------------------------------- ----------------------------------------------------------- ------- ---------
  IL-17                                                                                                                                                
    Before treatment   37.25±8.67                                                  38.47±8.47                                                  1.021     0.308
    After treatment    29.68±7.38^[a](#tfn1-etm-0-0-8273){ref-type="table-fn"}^    22.51±6.68^[a](#tfn1-etm-0-0-8273){ref-type="table-fn"}^    7.318   \<0.001
  IL-10                                                                                                                                                
    Before treatment   56.67±12.45                                                 57.58±13.22                                                 0.620     0.536
    After treatment    46.62±12.84^[a](#tfn1-etm-0-0-8273){ref-type="table-fn"}^   32.74±12.65^[a](#tfn1-etm-0-0-8273){ref-type="table-fn"}^   7.814   \<0.001
  IL-6                                                                                                                                                 
    Before treatment   58.24±12.65                                                 57.09±13.49                                                 0.630     0.529
    After treatment    45.25±11.68^[a](#tfn1-etm-0-0-8273){ref-type="table-fn"}^   34.68±12.55^[a](#tfn1-etm-0-0-8273){ref-type="table-fn"}^   6.248   \<0.001

P\<0.05, compared with the same group before treatment.

###### 

Analysis of neonatal adverse events \[n (%)\].

                 Control group (n=100)   Research group (n=106)   χ^2^    P-value
  -------------- ----------------------- ------------------------ ------- ---------
  Death          2 (2.00)                0                        2.020   0.155
  Malformation   5 (5.00)                0                        5.229   0.022
  Asphyxia       8 (8.00)                2 (1.89)                 3.914   0.048

###### 

Comparison of postpartum hemorrhage and postpartum hospital stays.

                                     Control group (n=100)   Research group (n=106)   χ^2^      P-value
  ---------------------------------- ----------------------- ------------------------ --------- ----------
  Postpartum hemorrhage (ml)         270.52±34.66            164.85±25.67             24.748    \<0.001
  Postpartum hospital stays (days)   12.63±4.62                8.52±3.54                7.113   \<0.0011

[^1]: Contributed equally
